For Taiwan's growing community of pet owners, a regulatory battle between pharmacists and veterinarians has become impossible to ignore — not least because their cats and dogs stand to bear the consequences.
What the New Rules Would Require
A regulation drafted two years ago by the Food and Drug Administration under the Ministry of Health and Welfare is scheduled to take effect on July 1. In plain terms, the new rules would require that human-grade pharmaceuticals used to treat pets — primarily dogs and cats — be purchased through licensed pharmacies rather than dispensed directly by veterinary clinics.
Supporters argue that bringing these drugs under formal oversight will improve transparency and safety. Critics, including most of the veterinary profession, contend the rules will add cost and inconvenience for pet owners while doing little to improve animal care. Veterinarians, for their part, are accused by some supporters of simply wanting to protect their control over drug dispensing as a revenue stream.
A Change That Solves Nothing — and Could Cost Lives
Setting aside the professional rivalry, the more important question is what this regulation actually does for pets and their owners. Even under the new system, it is still a veterinarian who diagnoses and prescribes. The only change is that the owner must then go to a pharmacy to fill the prescription.
It is difficult to see how that step meaningfully improves medication safety. In emergency situations — where speed matters — requiring owners to locate a pharmacy, purchase the drug, and return to the clinic before treatment can proceed could actively delay care and put animals at risk.
The End of One-Stop Veterinary Care
For pet owners, the new rules would effectively dismantle a system that has worked well for decades. The standard experience has been straightforward: bring your pet to the clinic, have it examined, vaccinated, and medicated in a single visit.
Sending owners to a separate pharmacy for every prescription turns routine care into a logistical burden — without improving medical outcomes, reducing costs, or enhancing safety. Drug prices, by some estimates, could rise by as much as 20％.
Why Drug Companies Won't Play Along
There is a technical exemption: if a pharmaceutical company registers a drug under the animal welfare category, it may supply that drug directly to veterinary clinics. But in practice, the incentive to do so is weak.
Taiwan's total dog and cat population is approximately three million. Of those, only an estimated five to ten％ require medical treatment at any given time, and because animals weigh roughly a tenth of what humans do, the volume of medication consumed is correspondingly small.
Of the 701 human-approved drugs currently listed as permissible for use in pets, fewer than 30％ have completed the registration process. Pharmaceutical companies have been candid about their reasoning: the market is simply too small to justify the administrative effort.
The Predictable Outcome: Supply Disruption
The practical consequence is predictable. Drug supplies to veterinary clinics could be cut off entirely, leaving veterinarians no choice but to issue written prescriptions that owners must fill at a pharmacy — precisely the outcome the regulation's critics warned about. No pet owner wants this. The new system adds complexity without adding value.
Regulators have scheduled a meeting bringing together pharmacists and veterinarians to discuss amendments. The revisions under consideration would allow veterinarians to maintain emergency and surgical drug supplies on hand, and would address the distribution of medical gases such as oxygen — a provision that became particularly controversial after reports circulated that pet owners might be required to bring their own oxygen cylinders to clinics when animals needed surgery.
The Question That Has Never Been Answered
Even with those adjustments, the fundamental problem remains. No regulator or pharmacist can guarantee that the right drug will be in a veterinarian's hands when a pet needs emergency treatment.
And the deeper question has never been convincingly answered: what does this regulation actually do for pets or their owners? Does it improve care? Does it reduce costs? If the honest answer is that it does neither — and may actively make things worse — there is no coherent case for proceeding on schedule.
Don't Fix What Isn't Broken
There is a sound principle in economic policy: when a market is functioning well, the best government action is usually restraint. Intervention disrupts existing equilibria, and when the baseline is already working, the disruption rarely produces a net social benefit. Taiwan's veterinary care system has served pet owners adequately. This regulation would trade that for bureaucratic complexity and higher costs.
The Lai Ching-te (賴清德) administration has already generated unnecessary controversy this year over other poorly conceived regulatory changes. It should not repeat that pattern here. The July 1 deadline for this pet drug regulation should be postponed — and the policy itself should be fundamentally rethought.
（Related：
The DPP Is Missing a Normal Person
｜
Latest
）
